Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Dermatologic 3

Conditions

Sezary Syndrome 3Mycosis Fungoides 3Lymphoma, T-Cell, Cutaneous 3Skin Neoplasms 2Lymphoma 2Melanoma 1Kidney Neoplasms 1

Interventions

Peripheral Blood Stem Cell Transplantation 38fludarabine phosphate 34Cyclophosphamide 29Mycophenolic Acid 25Cyclosporine 23Whole-Body Irradiation 22Tacrolimus 21Busulfan 18Antilymphocyte Serum 17Methotrexate 15Radiotherapy 14Flow Cytometry 13Filgrastim 13Etoposide 13Methylprednisolone 10Bortezomib 10Vorinostat 9Melphalan 9Therapeutics 8Psychiatric Rehabilitation 8Polymerase Chain Reaction 8Lenalidomide 8Rituximab 7Gemcitabine 7Cord Blood Stem Cell Transplantation 6Bexarotene 6tanespimycin 5fludarabine 5aldesleukin 5Transplantation 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Sezary Syndrome × zanolimumab × Dermatologic × Clear all
NCT00071071 2023-05-18

Clinical Trial of HuMax-CD4, a New Drug to Treat Early Stage T-Cell Lymphoma in the Skin.

Genmab

Phase 2 Completed
25 enrolled
DermatologicLymphoid

Lymphoma, Mycosis Fungoides, Sezary Syndrome, Skin Neoplasms, Lymphoma, T-Cell, Cutaneous

NCT00071084 2023-04-28

Clinical Trial of HuMax-CD4, a New Drug to Treat Advanced Stage T-Cell Lymphoma in the Skin.

Genmab

Phase 2 Completed
22 enrolled
DermatologicLymphoid

Lymphoma, Mycosis Fungoides, Sezary Syndrome, Skin Neoplasms, Lymphoma, T-Cell, Cutaneous

NCT00127881 2012-07-26

Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome

Emergent Product Development Seattle LLC

Phase 3 Terminated
76 enrolled
DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡